Cargando…
Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells
BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738693/ https://www.ncbi.nlm.nih.gov/pubmed/29262834 http://dx.doi.org/10.1186/s12944-017-0641-0 |
_version_ | 1783287742250090496 |
---|---|
author | Gbelcová, Helena Rimpelová, Silvie Knejzlík, Zdeněk Šáchová, Jana Kolář, Michal Strnad, Hynek Repiská, Vanda D’Acunto, Walter Cosimo Ruml, Tomáš Vítek, Libor |
author_facet | Gbelcová, Helena Rimpelová, Silvie Knejzlík, Zdeněk Šáchová, Jana Kolář, Michal Strnad, Hynek Repiská, Vanda D’Acunto, Walter Cosimo Ruml, Tomáš Vítek, Libor |
author_sort | Gbelcová, Helena |
collection | PubMed |
description | BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway’s intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12944-017-0641-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5738693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57386932017-12-21 Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells Gbelcová, Helena Rimpelová, Silvie Knejzlík, Zdeněk Šáchová, Jana Kolář, Michal Strnad, Hynek Repiská, Vanda D’Acunto, Walter Cosimo Ruml, Tomáš Vítek, Libor Lipids Health Dis Research BACKGROUND: Statin treatment of hypercholesterolemia is accompanied also with depletion of the mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) necessary for proper function of small GTPases. These include Ras proteins, prevalently mutated in pancreatic cancer. In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins. METHODS: These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). The effect of statins (atorvastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, rosuvastatin, and pitavastatin) and mevalonate intermediates on GFP-K-Ras protein translocation was analyzed using fluorescence microscopy. The changes in gene expression induced in MiaPaCa-2 cells treated with simvastatin, FPP, GGPP, and their combinations with simvastatin were examined by whole genome DNA microarray analysis. RESULTS: All tested statins efficiently inhibited K-Ras protein trafficking from cytoplasm to the cell membrane of the MiaPaCa-2 cells. The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway’s intermediates tested. Expressions of genes involved in metabolic and signaling pathways modulated by simvastatin treatment was normalized by the concurrent addition of FPP or GGPP. K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway. CONCLUSIONS: Our data indicate that the anticancer effects of statins observed in numerous studies to a large extent are mediated through isoprenoid intermediates of the mevalonate pathway, as they influence expression of genes involved in multiple intracellular pathways. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12944-017-0641-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-20 /pmc/articles/PMC5738693/ /pubmed/29262834 http://dx.doi.org/10.1186/s12944-017-0641-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gbelcová, Helena Rimpelová, Silvie Knejzlík, Zdeněk Šáchová, Jana Kolář, Michal Strnad, Hynek Repiská, Vanda D’Acunto, Walter Cosimo Ruml, Tomáš Vítek, Libor Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
title | Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
title_full | Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
title_fullStr | Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
title_full_unstemmed | Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
title_short | Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
title_sort | isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738693/ https://www.ncbi.nlm.nih.gov/pubmed/29262834 http://dx.doi.org/10.1186/s12944-017-0641-0 |
work_keys_str_mv | AT gbelcovahelena isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT rimpelovasilvie isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT knejzlikzdenek isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT sachovajana isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT kolarmichal isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT strnadhynek isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT repiskavanda isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT dacuntowaltercosimo isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT rumltomas isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells AT viteklibor isoprenoidsresponsibleforproteinprenylationmodulatethebiologicaleffectsofstatinsonpancreaticcancercells |